Several small single-center studies have reported a prognostic role for Ki-67 labeling index in advanced urothelial carcinoma of the urinary bladder. To investigate whether Ki-67 was a useful biomarker of oncological outcome after radical cystectomy for urothelial carcinoma, we assessed its expression in tumor tissue from 713 patients treated with radical cystectomy and bilateral lymphadenectomy at six centers. A high Ki-67 labeling index was independently associated with established features of aggressive urothelial carcinoma, disease recurrence, and cancer-specific survival. Addition of Ki-67 labeling index improved the accuracy of standard multivariate outcome prediction models, as measured by Harrell concordance index, by 2.9% for disease recurrence and 2.4% for bladder cancer -specific survival ( P < .001, two-sided MantelHaenszel) -a statistically and potentially clinically significant margin. In conclusion, routine assessment of Ki-67 expression status along with assessment of other established predictors of urothelial carcinoma outcome has the potential to improve identification of patients who are at increased risk for disease progression after radical cystectomy and thus may benefit from perioperative systemic chemotherapy. not shown). Kaplan -Meier analyses revealed that the Ki-67 cutoff of 20% was the best discriminator for both bladder cancer recurrence and survival.
of the bladder by testing whether Ki-67 labeling index improved the accuracy of predictive models that included standard histopathologic features (primary tumor stage and grade, lymph node status, and presence of lymphovascular invasion) for prediction of these outcomes.
The study cohort was composed of 713 patients who had been treated with radical cystectomy and bilateral pelvic lymphadenectomy between October 25, 1983, and July 7, 2005 , at six participating institutions. Histology, tumor grade, tumor stage, and presence of carcinoma in situ were confi rmed by blinded centralized rereview of the original pathology slides. No patients received systemic chemotherapy or external beam radiation before radical cystectomy. Adjuvant chemotherapy was administered to 187 (25.6%) patients. No patient underwent adjuvant radiation therapy.
Methods for staining and scoring for Ki-67 have been previously described ( 5 ) . Ki-67 labeling index was considered to be positive when samples demonstrated ≥ 20% reactivity. Utilizing the patient cohort reported in this study, we assessed the discriminative value of Ki-67 as categorical variable with serial increments of cutoffs ranging from 5% to 90% positive cells with regard to bladder cancer prognosis (data Radical cystectomy is the standard treatment for patients with refractory nonmuscle-invasive and muscle-invasive urothelial carcinoma of the urinary bladder. Despite advances in surgical techniques and perioperative chemotherapy, overall 5-year disease-specifi c survival after radical cystectomy remains approximately 50% ( 1 , 2 ) . Standard prognostic features such as pathological stage and grade are of limited use in predicting outcomes of these patients. Molecular biomarkers may provide a better understanding of the biology of an individual's tumor and may help stratify the heterogeneous patient population undergoing radical cystectomy into risk categories that can be used to guide the decision as to whether patients should be treated by observation or with adjuvant therapy ( 3 ).
Ki-67 is an established marker of cell proliferation that is present during the G1, S, G2, and M stages of the cell cycle ( 4 ) . We showed previously, in a cohort of 226 consecutive patients treated with radical cystectomy at a single academic center, that high Ki-67 labeling index was independently associated with disease recurrence and bladder cancer -specifi c mortality after adjusting for tumor stage, grade, and presence of lymphovascular invasion ( 5 ) . Despite additional studies that have added to our knowledge about molecular markers in bladder urothelial carcinoma, no markers are used for individualized treatment recommendations. This is largely due to the lack of external validation in large, multicenter studies. Moreover, the question of whether one or several of these biomarkers can improve the prognostic use of established predictors of cancer outcome requires more than the conventional univariate and multivariable analyses of association of these potential markers with disease outcomes. It must be established that the use of a potential biomarker adds unique information that improves the performance of a predictive model constructed without the new biomarker by a statistically signifi cant margin ( 3 , 6 ) . Therefore, we sought to validate our previous fi ndings that Ki-67 labeling index was independently associated with disease recurrence and death from bladder cancer in a large multi-institutional cohort of patients who were treated with radical cystectomy for urothelial carcinoma not shown). Kaplan -Meier analyses revealed that the Ki-67 cutoff of 20% was the best discriminator for both bladder cancer recurrence and survival.
Recurrence and survival probabilities after cystectomy were estimated using the Kaplan -Meier method. Univariate and multivariable Cox regression models were used to analyze time to recurrence and cancer-specifi c mortality after cystectomy. In all models, proportional hazards assumptions were systematically verifi ed using the Grambsch -Therneau residual-based test ( 7 ) . The change in predictive accuracy resulting from the addition of Ki-67 to standard predictor variables was quantifi ed with Harrell concordance index ( 8 , 9 ) . The area under the curve internal validation was performed using 200-bootstrap resamples ( 8 , 9 ) . With this statistical method, confidence intervals for predictive models are estimated by sampling with replacement from the original development sample. Internal validation was performed to obtain a realistic estimate of an upper limit of model performance for patients that are similar to those in the model development sample. Predictive accuracy estimates were expressed as proportions and compared with the Mantel -Haenszel test. All reported P values were derived from two-sided tests, and the threshold of statistical signifi cance was .05. All statistical tests were performed with S-Plus Professional (MathSoft Inc, Seattle, WA).
Bladder cancer recurred in 318 (44.6%) of 713 patients. At the time of analysis, 395 (55.4%) individuals had died, 274 (38.4%) of metastatic bladder cancer. Median follow-up was 57.6 months (range = 1 -236 months) for patients who were alive at the time of analysis. The distribution of clinical and pathological characteristics of the study patients according to Ki-67 expression revealed that Ki-67 overexpression was statistically signifi cantly associated with advanced pathological stage, higher tumor grade, lymphovascular invasion, and lymph node metastases ( Table 1 ) .
Ki-67 overexpression was also statistically signifi cantly associated with an increased probability of disease recurrence (hazard ratio [HR] = 2.76; 95% confi dence interval [CI] = 1.28 to 3.82; P < .001; Figure 1 , A ) and bladder cancer -specifi c mortality (HR = 2.3; 95% CI = 1.14 to 3.73; P < .001; Figure 1 , B ). The associations of Ki-67 expression with recurrence and cancer-specifi c survival oncological outcomes were also statistically signifi cant in patients with pathological T1-3, N0 (pT1-3, pN0) disease, as defi ned by the American Joint Committee on Cancer ( Figure 1 , C and D ) ( 10 ) .
In multivariable analyses that adjusted for the effects of sex (male vs female), age (continuous), pathological stage (T1 vs T2 vs T3 vs T4), pathological grade (low vs high), number of lymph nodes removed (continuous), number of positive lymph
CONTEXT AND CAVEATS

Prior knowledge
A high Ki-67 labeling index had been associated with poor clinical outcomes after radical cystectomy for bladder cancer.
Study design
Regression models were used to assess Ki-67 labeling index as a prognostic marker for disease recurrence and survival in an international, multicenter cohort of patients treated with radical cystectomy and bilateral lymphadenectomy for urothelial bladder cancer.
Contribution
High Ki-67 labeling index was independently associated with cancer recurrence and survival after radical cystectomy. Addition of the Ki-67 status to multivariate models including standard clinical predictors improved their predictive accuracy, measured by Harrell concordance index, by a statistically significant margin.
Limitations
Retrospective data collection may have introduced substantial case selection bias, and reproducibility of immunohistochemical staining and scoring for Ki-67 has not been demonstrated.
Implications
The addition of Ki-67 labeling index to prediction models incorporating standard pathological features, such as stage, grade, and lymphovascular invasion, may improve identification of patients who are at increased risk for disease progression after radical cystectomy and thus may benefit from treatment with adjuvant multimodal therapy. . Survival was estimated using the Kaplan -Meier method, and curves with 95% confi dence intervals (CIs) were constructed as time-to-event plots. Recurrence-free and bladder cancer -specifi c survival was the interval from cystectomy to the date of the fi rst observation of relapse or the date of death from bladder cancer. If no progression was reported and no death due to bladder cancer occurred, data on disease-free survival were censored from the date when the absence or relapse was last confi rmed or at the time of death from other causes. Differences between the curves were tested for statistical signifi cance using log-rank statistics (two-sided). HR = hazard ratio. nodes (continuous), surgical margin status (negative vs positive), lymph node metastases (absent vs present), lymphovascular invasion (absent vs present), and concomitant carcinoma in situ (absent vs present), Ki-67 was independently associated with both disease recurrence and cancer-specifi c survival ( Tables 2 and 3 ). Adjustment for the therapeutic effects of adjuvant chemotherapy did not change the statistical signifi cance of any of the analyses. For a marker to have clinical value, it must improve the predictive accuracy of a model that includes standard variables by a statistically and clinically signifi cant margin. We found that addition of the Ki-67 status to a standard multivariable model, which included tumor stage, grade, nodal status, and the presence of lymphovascular invasion, enhanced its predictive accuracy by 2.9% for disease recurrence and 2.4% for cancer-specifi c survival. In a subgroup of patients with clinically localized bladder cancer (pT1-3, pN0, Tables 2 and 3 ) , addition of Ki-67 to the standard model improved prediction of disease recurrence by 4.1% and that of cancer-specifi c mortality by 4.6% ( P < .001).
From the Editors
The chemosensitivity of urothelial carcinoma provides a strong rationale for using perioperative systemic chemotherapy to reduce development of systemic metastatic disease and improve survival after radical cystectomy ( 11 -14 ) . Modest oncological benefi ts achieved with perioperative chemotherapy for urothelial carcinoma of the urinary bladder are comparable with those achieved in lung, breast, and colon cancers. However, according to data from the National Cancer Database, perioperative chemotherapy is administered to only 12% of patients undergoing radical cystectomy ( 15 ) . Although multiple factors likely account for the relatively infrequent use of adjuvant systemic therapy, of major importance is the current inability to accurately predict individual patient's disease outcomes based on available clinical and pathological factors. Efforts to improve prediction for individuals have led to the evaluation of numerous molecules as potential biomarkers for disease progression ( 16 ) . However, despite intensifi ed interest, no molecular markers are used in clinical practice to guide patient selection for perioperative systemic therapy. Promising biomarkers are infrequently validated in large contemporaneous patient cohorts or add little prognostic information to the established clinical and/or pathological markers of disease ( 17 ) . Indeed, previous studies on Ki-67 were limited by small sample size, single institution design, and failure to assess the change in predictive accuracy with addition of Ki-67 to standard predictors ( 5 , 18 -23 ) .
The results of this study validate the strong predictive power of Ki-67 in a large multi-institutional cohort of patients treated with radical cystectomy for bladder urothelial carcinoma. More importantly, our data indicate that Ki-67 status adds statistically signifi cant predictive power to routinely assessed markers of disease, such as pathological tumor stage, grade, lymphovascular invasion, and nodal status. Predictive advantage offered by Ki-67 is especially robust in patients with clinically localized bladder cancer (pT1-3, pN0), a group for whom there is currently no rational strategy for recommendation of adjuvant systemic therapy.
Our study has some limitations. The retrospective design has potential limitations of case selection bias and data quality. In addition, reliability and reproducibility of immunohistochemical assessment of Ki-67 status has not been demonstrated.
The study also has strengths. We used standardized, automated, and reproducible immunohistochemical data acquisition and analysis methodologies that would be available in the community and in academic centers. Our conclusions are strengthened by bootstrapping analysis, which was performed for internal validation and to reduce overfi t bias.
